Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of “Hold” from Brokerages

Posted by Francis Steltz on Oct 4th, 2026

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) has earned a consensus rating of “Hold” from the eleven ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $25.70.

EYPT has been the topic of a number of analyst reports. HC Wainwright reiterated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, August 18th. Wall Street Zen upgraded shares of Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, September 27th. Cantor Fitzgerald cut shares of Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday, August 17th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $5.00 target price on shares of Eyepoint Pharmaceuticals in a report on Tuesday, August 18th. Finally, Weiss Ratings upgraded shares of Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, September 1st.

View Our Latest Stock Analysis on Eyepoint Pharmaceuticals

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. KBC Group NV acquired a new stake in shares of Eyepoint Pharmaceuticals in the 1st quarter valued at approximately $29,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Eyepoint Pharmaceuticals in the second quarter valued at approximately $72,000. Pictet Asset Management Holding SA acquired a new position in Eyepoint Pharmaceuticals during the first quarter worth $141,000. Engineers Gate Manager LP acquired a new position in Eyepoint Pharmaceuticals during the second quarter worth $161,000. Finally, MCF Advisors LLC raised its position in Eyepoint Pharmaceuticals by 8.3% in the fourth quarter. MCF Advisors LLC now owns 14,921 shares of the company’s stock worth $273,000 after acquiring an additional 1,149 shares in the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Stock Up 0.6%

EYPT opened at $3.25 on Tuesday. Eyepoint Pharmaceuticals has a 52 week low of $3.10 and a 52 week high of $19.11. The business has a 50 day moving average price of $6.87 and a two-hundred day moving average price of $11.10. The company has a market cap of $280.18 million, a PE ratio of -0.87 and a beta of 1.67.

Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The company had revenue of $0.51 million during the quarter, compared to analysts’ expectations of $0.45 million. As a group, sell-side analysts expect that Eyepoint Pharmaceuticals will post -3.51 EPS for the current fiscal year.

About Eyepoint Pharmaceuticals

(Get Free Report)

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.